{"id":793,"date":"2019-10-11T16:51:01","date_gmt":"2019-10-11T03:51:01","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=793"},"modified":"2019-10-23T09:15:25","modified_gmt":"2019-10-22T20:15:25","slug":"treatment-pathways-for-active-cll","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=793","title":{"rendered":"Treatment Pathways for Active CLL"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column width=&#8221;1\/1&#8243;][vc_custom_heading heading_semantic=&#8221;h1&#8243; text_size=&#8221;h1&#8243;]<strong>Treatment Pathways for Active CLL<\/strong>[\/vc_custom_heading][vc_column_text]This is the second in a series of slides from the recent CLL conference in Edinburgh that may be of interest to CLL patients.<\/p>\n<p><a href=\"https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/10\/CLL-Treatment-pathways-2.png\"><img decoding=\"async\" class=\"alignnone wp-image-800 size-large\" src=\"https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/10\/CLL-Treatment-pathways-2-1024x802.png\" alt=\"\" width=\"840\" height=\"658\" srcset=\"https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/10\/CLL-Treatment-pathways-2-1024x802.png 1024w, https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/10\/CLL-Treatment-pathways-2-300x235.png 300w, https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/10\/CLL-Treatment-pathways-2-768x602.png 768w, https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/10\/CLL-Treatment-pathways-2.png 1376w\" sizes=\"(max-width: 840px) 100vw, 840px\" \/><\/a><\/p>\n<p>This summarises current treatment options for active CLL and lists risk factors that would influence treatment decisions.<\/p>\n<p>Abbreviations:<\/p>\n<p>CIT = chemoimmunotherapy, eg FCR (fludarabine, cyclophosphamide, rituximab)<\/p>\n<p>Allo SCT = allogeneic stem cell transplant with stem cells from another matching person &#8211; related or unrelated. In practical terms, it is uncommonly done, can cause GVH (graft versus host disease), and is recognised as a potential cure for CLL .<\/p>\n<p>MRD = minimal residual disease, ie remission.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>This summarises current treatment options for active CLL and lists risk factors that would influence treatment decisions.<\/p>\n","protected":false},"author":1,"featured_media":794,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,19],"tags":[],"class_list":["post-793","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-news-media","category-cll-horizons-highlights","post_format-post-format-video"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/10\/CLL-Treatment-pathways.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=793"}],"version-history":[{"count":7,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/793\/revisions"}],"predecessor-version":[{"id":806,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/793\/revisions\/806"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/794"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}